Cargando…

Prolonged Honeymoon Period in a Thai Patient with Adult-Onset Type 1 Diabetes Mellitus

OBJECTIVE: To describe a usual case of adult-onset T1DM with prolonged honeymoon period for more than 5 years. METHODS: Repeated mixed meal stimulation tests for a period of 6–12 months together with monitoring pancreatic autoantibodies and laboratory data were followed following the onset of diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Thewjitcharoen, Yotsapon, Wanothayaroj, Ekgaluck, Jaita, Haruethai, Nakasatien, Soontaree, Butadej, Siriwan, Khurana, Ishant, Maxwell, Scott, El-Osta, Assam, Chatchomchuan, Waralee, Krittiyawong, Sirinate, Himathongkam, Thep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429022/
https://www.ncbi.nlm.nih.gov/pubmed/34513096
http://dx.doi.org/10.1155/2021/3511281
Descripción
Sumario:OBJECTIVE: To describe a usual case of adult-onset T1DM with prolonged honeymoon period for more than 5 years. METHODS: Repeated mixed meal stimulation tests for a period of 6–12 months together with monitoring pancreatic autoantibodies and laboratory data were followed following the onset of diagnosis. RESULTS: We report a 24-year-old Thai patient with T1DM with sustained remission without antidiabetic medication for more than 5 years while maintaining low-carbohydrate intake and regular exercise. Repeated mixed meal stimulation tests for a period of 6–12 months revealed preserved beta-cell functions. Interestingly, repeated pancreatic autoantibodies at 5 years after diagnosis still showed positive anti-GAD, anti-IA2, and anti-ZnT8. CONCLUSION: Restored beta-cell function with complete insulin withdrawal in new-onset T1DM has been reported in very few cases with some common factors as in our patient (low-carbohydrate intake with regular exercise). Delaying autoimmune activity by reducing metabolic load in newly diagnosed T1DM might play a role in maintaining the honeymoon period and could lead to an innovative therapeutic option in new-onset T1DM.